Vimian Group AB/Skr VIMIAN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Vimian Group AB
Vimian Group AB operates in the veterinary services industry, focusing on providing a range of specialized products and solutions for animal health. The company offers products and services across four key segments: Specialty Pharma, Diagnostics, Veterinary Services, and MedTech. These segments provide pharmaceuticals, diagnostic equipment, technology solutions, and veterinary services aimed at enhancing animal health and treatment. Founded in Sweden, Vimian Group AB is headquartered in Stockholm, from where it extends its operations globally. The company's strategic positioning is strengthened by its comprehensive range of products and services, allowing it to address diverse needs in the veterinary sector and support veterinarians through innovative solutions.
- Ticker
- Skr VIMIAN
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 1,033
- Headquarters
- Stockholm, Sweden
- Website
- vimian.com
Vimian Group AB Metrics
BasicAdvanced
kr 22B
54.73
kr 0.77
1.00
-
Price and volume
Market cap
kr 22B
Beta
1
52-week high
kr 42.75
52-week low
kr 24.18
Average daily volume
305K
Financial strength
Current ratio
2.731
Quick ratio
1.485
Long term debt to equity
0.363
Total debt to equity
0.369
Interest coverage (TTM)
4.65%
Profitability
EBITDA (TTM)
1,308.047
Gross margin (TTM)
68.86%
Net profit margin (TTM)
8.40%
Operating margin (TTM)
18.03%
Effective tax rate (TTM)
26.14%
Revenue per employee (TTM)
kr 4,954,720
Management effectiveness
Return on assets (TTM)
4.55%
Return on equity (TTM)
5.55%
Valuation
Price to earnings (TTM)
54.727
Price to revenue (TTM)
4.343
Price to book
30.16
Price to tangible book (TTM)
-191.83
Price to free cash flow (TTM)
23.858
Free cash flow yield (TTM)
4.19%
Free cash flow per share (TTM)
1.767
Growth
Revenue change (TTM)
10.90%
Earnings per share change (TTM)
16.53%
3-year revenue growth (CAGR)
12.87%
3-year earnings per share growth (CAGR)
49.35%
What the Analysts think about Vimian Group AB
Analyst ratings (Buy, Hold, Sell) for Vimian Group AB stock.
Analyst projections of the future price of Vimian Group AB stock.
Bulls say / Bears say
In Q2 2026, revenue rose 17% to EUR 121.6m, including 12% organic growth, while adjusted EBITA grew 17% and its margin edged up to 24.5%. That points to broad-based growth with some operating leverage. (Vimian)
MedTech’s organic growth returned to 11% in Q2, with US orthopaedics back to low single-digit growth and segment EBITA up 27%. The recovery supports a turnaround case, although US growth remains modest. (Stock Analysis)
Vimian had closed four acquisitions by mid-2026 and said its pipeline remained active across all four segments. Further deals could extend its reach and add to growth if they are integrated at sensible valuations. (Stock Analysis)
Operating cash flow fell to EUR 3.8m in Q2 from EUR 22.2m a year earlier, as working capital rose to 26% of revenue. If the cash drag persists, it could constrain debt reduction and acquisition capacity. (Vimian, Stock Analysis)
Net debt climbed to EUR 273.7m from EUR 258.4m in one quarter, while leverage remained at 2.1 times. Continued debt-funded acquisitions would leave less headroom if earnings or cash generation weaken. (Stock Analysis)
Management expects only slow, single-digit growth in US orthopaedics and said growth investments in MedTech and new Veterinary Services markets limit margin improvement for 2026. Profits could disappoint if the recovery takes longer than planned. (Stock Analysis, Vimian)
Data summarised monthly by Lightyear AI. Last updated on 16 Oct 2026.
Vimian Group AB Financial Performance
Revenues and expenses
Vimian Group AB Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Vimian Group AB
Fund name | Fund size | Skr VIMIAN weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.04% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.04% |
SPDR MSCI All Country World IM€SPYI | $7.7B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.